The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Innovate combines with RDD, but the success of the takeover relies in large part on a project for coeliac disease.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
The company insists that its sickle cell disease therapy Endari still has a future, despite questionable efficacy and the approach of new treatments.
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…